We are live on ! Find out more
Birchview Capital

Birchview Capital Portfolio holdings

AUM $173M Turnover 41.05%
1-Year Est. Return 89.27%
This Fund
S&P 500
This Quarter Est. Return
+5.97%
1 Year Est. Return
+89.27%
3 Year Est. Return
+315.46%
5 Year Est. Return
+442.13%
10 Year Est. Return
+979.78%
AUM
$194M
AUM Growth
+$4.56M
Cap. Flow
+$124K
Cap. Flow %
0.06%
Top 10 Hldgs %
92.1%
Holding
47
New
6
Increased
8
Reduced
4
Closed
7
Avg Time Held
1.6 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.6 years

Sector Composition

Rank Sector Weight
1 Healthcare 96.34%
2 Energy 2.46%
3 Industrials 0.44%
4 Consumer Staples 0.37%
5 Miscellaneous 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CELG
1
DELISTED
Celgene
CELG
$111M 57.33%
761,051
-14,000
-2% -$1.91M
2014 Q4
11 quarters
AXDX icon
2
DELISTED
Accelerate Diagnostics
AXDX
$49M 25.32%
218,380
– –
2014 Q4
11 quarters
VRML
3
DELISTED
Vermillion
VRML
$4.43M 2.29%
2,462,933
+180,000
+8% +$265K
2014 Q4
11 quarters
NBIX icon
4
Neurocrine Biosciences
NBIX
$15.8B
$3.21M 1.66%
52,400
+27,200
+108% +$1.44M
2015 Q3
8 quarters
EQT icon
5
EQT
EQT
$30.8B
$2.76M 1.43%
77,705
– –
2014 Q4
11 quarters
CORT icon
6
Corcept Therapeutics
CORT
$7.02B
$1.83M 0.95%
95,000
– –
2015 Q4
7 quarters
QDEL icon
7
QuidelOrtho
QDEL
$612M
$1.71M 0.88%
38,975
– –
2014 Q4
11 quarters
OVV icon
8
Ovintiv
OVV
$16.5B
$1.56M 0.8%
26,460
– –
2014 Q4
11 quarters
AAAP icon
9
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$1.49M 0.77%
22,000
+2,000
+10% +$97.1K
2017 Q1
2 quarters
OXFD
10
DELISTED
Oxford Immunotec Global
OXFD
$1.3M 0.67%
77,303
+10,000
+15% +$163K
2015 Q3
8 quarters
CFRX
11
DELISTED
ContraFect
CFRX
$1.26M 0.65%
1,419
+513
+57% +$485K
2015 Q2
9 quarters
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$222M
$1.22M 0.63%
68,000
– –
2016 Q4
3 quarters
VCYT icon
13
Veracyte
VCYT
$2.02B
$1.04M 0.54%
118,767
+20,000
+20% +$163K
2016 Q3
4 quarters
SIEN
14
DELISTED
Sientra
SIEN
$975K 0.5%
6,330
– –
2015 Q3
8 quarters
XLRN
15
DELISTED
Acceleron Pharma
XLRN
$933K 0.48%
25,000
+10,000
+67% +$347K
2017 Q2
1 quarter
SITO
16
DELISTED
Sito Mobile
SITO
$857K 0.44%
120,000
-20,000
-14% -$95.6K
2016 Q2
5 quarters
WMGI
17
DELISTED
Wright Medical Group
WMGI
$776K 0.4%
30,000
– –
2015 Q4
7 quarters
BIOL icon
18
DELISTED
Biolase
BIOL
$775K 0.4%
103
– –
2014 Q4
11 quarters
YTEN icon
19
DELISTED
Yield10 Bioscience
YTEN
$722K 0.37%
236
– –
2014 Q4
11 quarters
MASI icon
20
DELISTED
Masimo
MASI
$692K 0.36%
8,000
– –
2014 Q4
11 quarters
TSRO
21
DELISTED
Tesaro
TSRO
$671K 0.35%
5,200
– –
2015 Q4
7 quarters
MRK icon
22
Merck
MRK
$327B
$640K 0.33%
10,480
– –
2014 Q4
11 quarters
VYGR icon
23
Voyager Therapeutics
VYGR
$100M
$494K 0.26%
+24,000
New +$271K
2017 Q3
0 quarters
PXD icon
24
DELISTED
Pioneer Natural Resources
PXD
$443K 0.23%
3,000
– –
2014 Q4
11 quarters
CELGZ
25
DELISTED
Celgene Contingent Value Rights
CELGZ
$443K 0.23%
291,877
– –
2014 Q4
11 quarters

Similar funds

Birchview Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Birchview Capital held 47 positions worth $194M, up 2.4% from $189M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Birchview Capital's Q3 2017 filing shows 6 new, 8 increased, 4 reduced and 7 closed positions. Its largest new stake was Intercept Pharmaceuticals: 4,300 shares worth $250K. The largest sale was Celgene, an estimated $1.91M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Industrials.

  • Birchview Capital's largest Q3 2017 buy was Intercept Pharmaceuticals: 4,300 shares worth $250K.
  • Birchview Capital added most to Neurocrine Biosciences in Q3 2017, an estimated $1.44M increase.
  • Birchview Capital's biggest Q3 2017 reduction was Celgene, cutting an estimated $1.91M.
  • Birchview Capital fully exited NxStage Medical in Q3 2017, selling an estimated $857K.
  • Birchview Capital's ten largest holdings make up 92% of its $194M portfolio in Q3 2017.
  • Birchview Capital opened 6 new positions and closed 7 in Q3 2017.
  • Birchview Capital's portfolio value rose 2.4% quarter-over-quarter to $194M.

Based on Birchview Capital's 13F filing for Q3 2017, filed 2 Nov 2017.